ASTRAZENECA PLC DL-25/ GB0009895292 /
8/23/2024 1:18:17 PM | Chg. +1.8000 | Volume | Bid10:00:17 PM | Ask10:00:17 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
155.3500EUR | +1.17% | 63 Turnover: 9,772.0500 |
154.0500Bid Size: 50 | 155.9000Ask Size: 50 | 237.77 bill.EUR | - | - |
GlobeNewswire
8/12
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune...
GlobeNewswire
8/8
Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets...
GlobeNewswire
6/26
As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire
6/20
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Gr...
GlobeNewswire
6/18
Mika Health Collaborates with AstraZeneca and Daiichi Sankyo to Deliver AI-Enabled Mobile Support to...
GlobeNewswire
6/18
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
6/13
Rheumatologists' Aggressive Approach to SLE Treatment Targets Specific Patient Types with Biologics
GlobeNewswire
5/8
Annual NMDP Gala in New York Raises More Than $560,000, Enabling More Patients to Receive Life-Savin...
GlobeNewswire
5/8
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Bi...
GlobeNewswire
4/1
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent ...
GlobeNewswire
3/28
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Pati...